Clinical Edge Journal Scan

Increased prevalence of subclinical myocardial dysfunction in PsA with higher disease activity


 

Key clinical point: Patients with moderate-high psoriatic arthritis (PsA) disease activity without traditional cardiovascular risk factors had an increased prevalence of subclinical myocardial dysfunction, lower adiponectin levels, and higher serum interleukin-17A (IL-17A) levels.

Major finding: Patients with moderate and high PsA disease activity had lower global longitudinal strain (GLS), tricuspid annular plane systolic excursion, left ventricular ejection fraction, and adiponectin levels and higher IL-17A levels compared with patients with low PsA disease activity and control individuals (all P < .05). GLS was significantly associated with serum IL-17A ( P = .001) and adiponectin ( P = .032) levels.

Study details: This study included 55 patients with PsA and 25 control individuals without cardiovascular disease.

Disclosures: This study did not disclose the funding source. The authors declared no conflict of interests.

Source: Pletikosic I et al. Association of inflammatory biomarkers and disease activity with subclinical myocardial dysfunction in psoriatic arthritis. Sci Rep. 2023;13(1):10371 (Jun 26). Doi: 10.1038/s41598-023-37412-6.

Recommended Reading

Patients with PsA, especially women, likely to have abnormal sleep behavior
Psoriatic Arthritis ICYMI
Higher disease burden among women with PsA vs RA
Psoriatic Arthritis ICYMI
High physical activity reduces visceral fat mass and percentage body fat in PsA
Psoriatic Arthritis ICYMI
Commentary: Evaluating new and established treatments for PsA, July 2023
Psoriatic Arthritis ICYMI
Beta-defensin-2 may serve as a predictive biomarker for clinical response to secukinumab in PsA
Psoriatic Arthritis ICYMI
Predictors of treatment response in PsA patients initiating a first TNFi
Psoriatic Arthritis ICYMI
Real-world study confirms clinical efficacy of ixekizumab in PsA
Psoriatic Arthritis ICYMI
Apremilast offers a safe long-term oral treatment option for psoriatic arthritis
Psoriatic Arthritis ICYMI
Improvement in patient-reported outcomes comparable with ustekinumab and TNFi in PsA
Psoriatic Arthritis ICYMI
Anti-TNF-α therapy reduces incidence of nailfold capillaroscopic abnormalities in PsA
Psoriatic Arthritis ICYMI